SCHEMBL319003

SCHEMBL319003

COC(=O)c1sc(C#CC2CC2)cc1NCC(=O)N1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.41
CYP2E1 P05181 1/20 0.38
ALDH1A1 P00352 5/20 0.36
HTT P42858 2/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 3/20 0.35
FKBP1A P62942 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ACHE P22303 1/20 0.35
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
MGLL Q99685 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GAA P10253 1/20 0.34
RAB9A P51151 1/20 0.34
GLA P06280 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
IKBKB O14920 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10265709 0.86 PTGS2 (0.43) PTGS2CYP2E1ALDH1A1HTTKDM4E
SCHEMBL325276 0.85 CYP2E1 (0.47) PTGS2CYP2E1ALDH1A1HTTKDM4E
SCHEMBL318967 0.84 PTGS2 (0.41) PTGS2CYP2E1ALDH1A1HTTKDM4E
SCHEMBL318187 0.83 PTGS2 (0.41) PTGS2CYP2E1ALDH1A1HTTKDM4E
SCHEMBL324985 0.83 PTGS2 (0.41) PTGS2CYP2E1ALDH1A1HTTKDM4E
SCHEMBL10265728 0.81 PTGS2 (0.45) PTGS2ALDH1A1HTTKDM4EPOLB
SCHEMBL10265406 0.77 RAF1 (0.47) PTGS2
SCHEMBL319096 0.77 PTGS2 (0.43) PTGS2ALDH1A1HTTKDM4EPOLB
SCHEMBL10265436 0.76 PTGS2 (0.45) PTGS2ALDH1A1HTTKDM4EPOLB
SCHEMBL10265386 0.76 PTGS2 (0.44) PTGS2ALDH1A1HTTKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-25 US disclosed
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-25 US disclosed
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-25 US disclosed
EP-2585447-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2013-05-01 EP disclosed
WO-2012006055-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-12 WO disclosed
WO-2012006055-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS SLC10A1, ACE, CEL PTGS2 3078/4885CYP2E1 1027/4885ALDH1A1 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.